What should I eat if I am resistant to Brigatinib/Brigatinib?

When patients develop drug resistance after treatment with Brigatinib/Brigatinib (Brigatinib), the treatment plan needs to be re-evaluated and other feasible treatment options need to be considered. Here are some possible options:

1.Next generationALKinhibitors: If the patient tolerates it well and has suitable genetic mutation characteristics, next generationALKinhibitors can be considered, such as olapatinib (Alectinib), lexitinib (Ceritinib) or entrectinib (Entrectinib). These drugs have different resistance mechanisms and can continue to exert their effects on resistance.

2.EGFRinhibitors: For NSCLC patients with EGFR mutations, you can try EGFR inhibitors, such as gefitinib (Gefitinib) or erlotinib (Erlotinib). These drugs are commonly used treatments for EGFR mutated NSCLC and can provide certain anti-tumor effects.

3.Chemotherapy drugs: Chemotherapy drugs remain a viable option, especially for patients who have experienced multiple targeted therapies and developed resistance. Chemotherapy drugs can inhibit the growth and spread of tumor cells through different mechanisms.

4.Immunotherapy: Immunotherapy is an emerging anti-cancer treatment method that inhibits tumor growth by activating the patient's own immune system. Immune checkpoint inhibitors, such as PD-1inhibitors and PD-L1inhibitors, have been widely used in NSCLCtreatment and may be an optional treatment option.

5.Clinical trials: Participating in a clinical trial is an opportunity to try new, potentially effective drugs and treatment strategies. Clinical trials can provide more personalized treatment options and provide patients with the latest treatments.

Selecting next steps in treatment should be determined by the physician based on the patient's specific circumstances, disease characteristics, and available treatment options. Therefore, patients need to work closely with their doctors to develop the best treatment plan and adjust the treatment plan in a timely manner to ensure the best results.

Brigatinib/Brigatinib has been launched in China and has been included in medical insurance. Since it has just been approved for marketing, patients may not be able to buy it in domestic pharmacies. If you need to purchase it in China, please consult the local pharmacy. However, the price is quite high, more than 10,000 yuan. Foreign Brigatinib/Brigatinib are mainly generic drugs, mainly Bangladeshi and Laos generic drugs. The price of the international version of the Bangladeshi generic drug Yaopin is about 2000yuan, the specification is 90mg*30 tablets; the price of the Laos version of the generic drug is about 600, and the specification is smaller. And the ingredients of domestic original drugs and foreign generic drugs are basically the same.